Jared Kaltwasser

The most common treatments come with significant cardiovascular risk, but study investigators suggest newer options might offer a more favorable risk profile.

Study authors say the consequences of misdiagnosing osteomyelitis can be severe in the disease setting of sickle cell disease (SCD).

Significant mechanobiological advances have not yet been incorporated into oncology treatment, the authors wrote. 

Authors describe 3 patients with cancer who were given interleukin-23 (IL-23) inhibitors for psoriasis or immune-related psoriasis.

Most cases of high-grade serous ovarian cancer are not diagnosed until the disease has reached an advanced stage.

Surgery can be difficult in such cases of diffuse large B-cell lymphoma (DLBCL), but it leads to significant better outcomes, study authors said.

A new review article illuminates why physicians should keep coagulation disorders in mind when evaluating patients with heavy abnormal uterine bleeding.

More than 4 in 10 participants received a rare disease diagnosis as a result of the analysis.

Patients with the chronic skin condition hidradenitis suppurativa were less likely to be hospitalized with COVID-19 vs a control group.

Black children with sickle cell disease (SCD) face a disproportionate burden of social determinants of health (SDOH), the study found.

The findings suggest existing therapies for other cancers may be helpful in multiple myeloma (MM).

The use of probiotics, fecal microbiota transplants, and live biotherapeutics have been effective in phase 3 studies that focus on Clostridioides difficile infection (CDI).

More attention should be paid to prevent acne scarring and address the psychosocial consequences associated with it, authors argue.

The patient in this case experienced significant muscle weakness after emerging from anesthesia.

The US government has set a goal of achieving viral clearance in 80% of patients by 2030.

Investigators said it is important for clinicians to interpret scans with knowledge of case-specific context for patients with diffuse large B-cell lymphoma (DLBCL).

Rates of next-generation sequencing (NGS) more than doubled once a nurse navigation program was implemented.

Investigators found no significant impact on survival, however.

Modeling done based on data from a single hospital suggests a transmission-prevention regime meaningfully reduced hospital-onset Clostridioides difficile infection (CDI).

Serial biopsies help explain why patients with late relapses of diffuse large B-cell lymphoma (DLBCL) fare better than those with early relapses.

The therapy is still not widely used among older patients who have diffuse large B-cell lymphoma (DLBCL).

More data are needed to confirm the findings and assess individual risk levels, the authors said.

The patient was put on chemotherapy, but then underwent surgical resection following an accident at home.

Investigators say their data show the importance of vaccination and antibiotic stewardship programs.

A new review outlines strategies that may help reduce the risk of severe cytokine release syndrome (CRS) for patients treated with immunotherapy.

Shifts in clinical treatment patterns could prompt investigators to revisit the cost-effectiveness question.

Considering the depth and durability of responses with axicabtagene ciloleucel (axi-cel) in large B-cell lymphoma (LBCL), the investigators added that CAR T cells should no longer be seen as a therapy only for heavily pretreated patients, but also as an option for earlier lines of therapy.

Data presented at the 2023 European Hematology Association Annual Meeting showed positive outcomes in patients with follicular lymphoma and large B-cell lymphoma, and further evaluation in diffuse large B-cell lymphoma is ongoing.

Investigators found important differences that may help clinicians better understand how to manage toxicities associated with the therapy.

The findings, which suggest that axicabtagene ciloleucel (axi-cel) may be a good option for a patient group often deemed ineligible for other curative-intent therapy, come from a planned subgroup analysis from the ZUMA-7 trial.